In summary, we show that aggregated neuronal and oligodendroglial 4R-tau translates to measurable tau PET signals in patients with PSP and CBS, whereas astrocytic and axonal tau inclusions are a minor source of in vivo PET signals. The gene discussed is MAPT; the disease is supranuclear palsy, progressive, 1.